Danish biotech Genmab announced plans to acquire Dutch company Merus in an $8 billion all-cash deal. The acquisition brings Merus’s promising head and neck cancer bispecific antibody, petosemtamab, into Genmab’s portfolio. Petosemtamab recently showed encouraging preliminary survival benefits in Phase 2 trials combined with pembrolizumab and is currently in late-stage Phase 3 testing. This move aligns with Genmab’s strategy to bolster its presence in oncology, expecting potential market entry around 2027.